Program
Safiglipron
Also written as “HRS-7535”, “HRS-7535 tablet” and “HRS-7535 Tablets”.
In Jiangsu HengRui Medicine's pipeline, GLP-1
. Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Renal Insufficiency, Chronic · Diabetic Nephropathies, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 193 open or running | phase 3since Sep 6, 2024 | Apr 20, 2022 | Dec 2026phase 2 · NCT06820099 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-7535
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Apr 20, 2022.
- May 14, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06422039 · 24 enrolled · China
- Jul 3, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06495931 · 24 enrolled · China
- Sep 6, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06589765 · 810 enrolled · China
- Sep 29, 2024Phase 2 study in OverweightNCT06621316 · 74 enrolled · China
- Oct 23, 2024Phase 2 study in Chronic Weight ManagementNCT06671821 · 81 enrolled · China
- Nov 1, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06672172 · 284 enrolled · China
- Dec 6, 2024Phase 1 study in Diabetes MellitusNCT06727838 · 18 enrolled · China
- Feb 5, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT06819488 · 6 enrolled · China
- Feb 6, 2025Phase 2 study in ObesityNCT06820099 · 225 planned · China
- Mar 25, 2025Phase 3 study in OverweightNCT06904105 · 556 enrolled · China
- May 6, 2025Phase 1 study in Diabetes MellitusNCT06961643 · 24 enrolled · China
- Nov 26, 2025Phase 1 study in ObesityNCT07269756 · 40 enrolled · China
- Apr 7, 2026Phase 3 study in ObesityNCT07528027 · 648 planned · China
- May 29, 2026Phase 3 study in Renal Insufficiency, ChronicNCT07625774 · 3,690 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in ObesityNCT06820099
- Dec 2027Primary completion: phase 3 study in ObesityNCT07528027
- May 2031Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT07625774
TargetBeta
“GLP-1”the company's pipeline, read by Claude · source
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| efpeglenatiderule | Hanmi Pharmaceutical | phase 3 | 13 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07625774Renal Insufficiency, Chronic · China | 3 | Not yet recruiting | May 2031 | 3,690 |
| NCT07528027Obesity · China | 3 | Recruiting | Dec 2027 | 648 |
| NCT07269756Obesity · China | 1 | Completed | Mar 8, 2026 | 40 |
| NCT06961643Diabetes Mellitus · China | 1 | Completed | Jan 22, 2026 | 24 |
| NCT06904105Overweight · China | 3 | Completed | Apr 17, 2026 | 556 |
| NCT06820099Obesity · China | 2 | Recruiting | Dec 2026 | 225 |
| NCT06819488Diabetes Mellitus, Type 2 · China | 1 | Completed | Apr 16, 2025 | 6 |
| NCT06727838Diabetes Mellitus · China | 1 | Completed | Jan 25, 2025 | 18 |
| NCT06672172Diabetes Mellitus, Type 2 · China | 3 | Completed | Nov 13, 2025 | 284 |
| NCT06671821Chronic Weight Management · China | 2 | Completed | Aug 15, 2025 | 81 |
| NCT06621316Overweight · China | 2 | Completed | Jul 14, 2025 | 74 |
| NCT06589765Diabetes Mellitus, Type 2 · China | 3 | Completed | May 29, 2026 | 810 |
| NCT06495931Diabetes Mellitus, Type 2 · China | 1 | Completed | Aug 13, 2024 | 24 |
| NCT06422039Diabetes Mellitus, Type 2 · China | 1 | Completed | Aug 6, 2024 | 24 |
| NCT06415214Diabetic Nephropathies · China | 2 | Completed | Jul 15, 2025 | 281 |
| NCT06393348Diabetes Mellitus, Type 2 · China | 2 | Completed | Nov 15, 2024 | 155 |
| NCT06132204Diabetes Mellitus, Type 2 · China | 1 | Completed | Mar 13, 2024 | 16 |
| NCT05759897Diabetes Mellitus, Type 2 | 2 | UNKNOWN | Dec 21, 2023 | 180 |
| NCT05347758Healthy Subjects | 1 | UNKNOWN | Sep 18, 2022 | 106 |
How it is read
Names in the registry
- “HRS-7535”, 7 entries
- “HRS-7535 tablet”, 5 entries
- “HRS-7535 Tablets”, 3 entries
- “HRS-7535 tablets”, 2 entries
- “HRS-7535 Tablet”, 1 entry
Codes read as this program: HRS7535.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 8 studies
- Obesity, 5 studies
- Diabetes Mellitus, 2 studies
- Renal Insufficiency, Chronic, 1 study
- Diabetic Nephropathies, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.